Abbott Laboratories (ABT)

Abbott Laboratories' stock has shown robust performance, with a 16.67% return and a 17.13% year-to-date increase as of June 23, 2025. The company's Q4 fiscal 2024 earnings report highlighted a 9.5% sales growth and a 13% increase in adjusted earnings per share. For Q1 CY2025, Abbott met Wall Street's revenue expectations with 4% year-on-year growth and surpassed analyst estimates for non-GAAP profit. Abbott also declared its 406th consecutive quarterly dividend on June 13, 2025. Insider trading activity in the past six months has primarily involved sales. Analysts generally maintain a positive outlook, with a Strong Buy consensus and an average price target of $143.26 as of June 29, 2025. Recent product-related news includes Health Canada's authorization for Abbott's whole blood rapid test and new research on Abbott's Healthy Food Rx Program.

While detailed breakdowns are not extensively provided, Abbott's overall seasonality profile measures average price changes over time by calendar month. Demand for certain product lines, such as diagnostics, can be influenced by seasonal factors like the cold/flu/COVID season. Given its diverse portfolio, demand for Abbott's products may vary depending on the specific product category and prevailing health trends.

Abbott Laboratories is a global healthcare company with a diversified portfolio spanning Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. It is a leader in the healthcare sector, specifically within the Healthcare Equipment & Supplies and Medical Instruments & Supplies industries. Its major products include medical devices, diagnostic products, nutritional products, and established pharmaceutical products.

Abbott Laboratories has a significant global presence, operating in over 160 countries, with approximately 60% of its sales generated outside the United States. It has manufacturing facilities and distribution networks spanning numerous countries, serving healthcare needs across both developed and developing markets. Specific regional operations for its Diabetes Care business include headquarters in the San Francisco Bay Area, Milpitas, Wiesbaden, Singapore, and a presence in Latin American countries. Key manufacturing sites for Diabetes Care are located in Donegal, Ireland, and Witney, United Kingdom.

Abbott Laboratories maintains a strong brand reputation due to its well-established brands and high customer satisfaction. The company is recognized for its commitment to sustainability and ethical business practices, with continuous investment in research and development contributing positively to its public image.

Institutional investors hold a significant majority of Abbott Laboratories' shares, accounting for approximately 76% to 77.37% of the company's stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors hold about 21.49% of the shares, while company insiders own less than 1%.